Beta Bionics (BBNX) director gets stock grant, sells 1,998 shares under plan

Rhea-AI Filing Summary

Beta Bionics, Inc. director Adam Lezack reported a mix of stock awards and small planned sales. On May 21, 2026, he received a grant of 16,965 shares of Common Stock at no cost, described as a restricted stock unit award under the company’s 2025 Equity Incentive Plan.

That same day he executed an open-market sale of 1,000 shares at $9.95 per share, followed by a sale of 998 shares at $11.21 per share on May 22, 2026. The filing shows he held 27,399 shares directly after the most recent sale. Both sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 1,998 shares ($21,138)

Net Sell 3 txns

Insider Lezack Adam

Role null

Sold 1,998 shs ($21K)

Type	Security	Shares	Price	Value
Sale	Comon Stock	998	$11.21	$11K
Sale	Common Stock	1,000	$9.95	$10K
Grant/Award	Common Stock	16,965	$0.00	--

Holdings After Transaction: Comon Stock — 27,399 shares (Direct, null); Common Stock — 11,432 shares (Direct, null)

Footnotes (1)

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

Key Figures

RSU grant: 16,965 shares First open-market sale: 1,000 shares at $9.95/share Second open-market sale: 998 shares at $11.21/share +2 more

5 metrics

RSU grant 16,965 shares Restricted stock unit award on May 21, 2026

First open-market sale 1,000 shares at $9.95/share Common Stock sale on May 21, 2026

Second open-market sale 998 shares at $11.21/share Common Stock sale on May 22, 2026

Net shares sold 1,998 shares Total sale volume across two transactions

Shares held after latest sale 27,399 shares Direct ownership following May 22, 2026 sale

Key Terms

Rule 10b5-1 Plan, restricted stock unit, Equity Incentive Plan, open-market sale

4 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock unit financial

"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Equity Incentive Plan financial

"restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

open-market sale financial

"transaction_action: "open-market sale" for Common Stock transactions on May 21 and May 22, 2026."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lezack Adam

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		S(1)		1,000	D	$9.95	11,432	D
Common Stock	05/21/2026		A		16,965(2)	A	$0	28,397	D
Comon Stock	05/22/2026		S(1)		998	D	$11.21	27,399	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025.

2. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

	/s/ Stephen Feider, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Beta Bionics (BBNX) director Adam Lezack report?

Adam Lezack reported one stock award and two small stock sales. He received 16,965 shares as a grant, then sold 1,000 shares at $9.95 and 998 shares at $11.21 in open-market transactions under a pre-arranged Rule 10b5-1 plan.

How many Beta Bionics (BBNX) shares does Adam Lezack hold after these Form 4 transactions?

After the most recent reported sale, Adam Lezack directly holds 27,399 shares of Beta Bionics common stock. This figure reflects his position following the May 22, 2026 open-market sale of 998 shares at $11.21 disclosed in the Form 4 filing.

Was the Beta Bionics (BBNX) director stock sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the shares sold were pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. Such plans pre-schedule trades, making the timing more routine and reducing the informational value of the specific sale dates.

What type of equity award did Adam Lezack receive from Beta Bionics (BBNX)?

He received a restricted stock unit award for 16,965 shares of common stock. The footnote explains this grant was made under Beta Bionics’ 2025 Equity Incentive Plan and is recorded as an acquisition at a price of $0.00 per share in the Form 4.

Were Adam Lezack’s Beta Bionics (BBNX) transactions open-market buys or sales?

The Form 4 records two open-market sales and no open-market purchases. He sold 1,000 shares at $9.95 and 998 shares at $11.21, while separately receiving 16,965 shares as a stock award, which is compensation rather than an open-market purchase.